12 Healthcare Stocks with Insider Buying in 2025

Page 3 of 10

8. Caris Life Sciences, Inc. (NASDAQ:CAI)

Insider Shares: 48.01%

Caris Life Sciences, Inc. (NASDAQ:CAI) is advancing its position as a leader in precision medicine by combining whole exome and transcriptome sequencing with AI-driven insights to support cancer detection, monitoring, and therapy selection.

The company delivered strong second-quarter results for 2025, reporting $181.4 million in revenue, up 81% year-over-year, with molecular profiling revenue climbing nearly 86%. Caris Life Sciences, Inc. (NASDAQ:CAI) completed more than 50,000 clinical therapy selection cases, while gross margins expanded to 62.7% from 37.5% a year ago. Importantly, the business turned profitable on an adjusted EBITDA basis, generating $16.7 million in EBITDA and $5.9 million in free cash flow. These strong fundamentals, combined with recent stocks with insider buying, underscore investor confidence in CAI’s growth trajectory.

Scientifically, CAI continues to strengthen its leadership in precision oncology. Recent findings published in the New England Journal of Medicine validated the company’s work on tumor-infiltrating clonal hematopoiesis (TI-CH), a phenomenon that can confound mutation analysis and treatment decisions. This reinforces CAI’s commitment to refining diagnostic accuracy in oncology.

Recently, Caris Life Sciences, Inc. (NASDAQ:CAI) highlighted the clinical validation of its MI Cancer Seek® assay, an FDA-approved AI-enabled liquid biopsy platform designed for early cancer detection, minimal residual disease monitoring, and therapy guidance. Recent studies demonstrated its broad clinical utility across solid tumors and tissue-agnostic settings, underscoring its potential as a transformative diagnostic tool.

The corporation also published new data on sequencing strategies in breast cancer subgroups, illustrating how its AI-driven molecular insights can directly inform treatment choices. Together, these advances showcase CAI’s focus on applying cutting-edge science and AI to deliver more precise, personalized cancer care.

Page 3 of 10